Public Market Listing
Live quotes, historical charts, and market capitalization for H. Lundbeck are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule | SchizophreniaBipolar Disorder | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Major Depressive DisorderSchizophreniaBipolar Disorder | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia | |
| Approved | GABA-A receptorSmall molecule | EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome | |
| Approved | norepinephrine precursorSmall molecule | Parkinson's DiseaseNeurogenic Orthostatic Hypotension | |
| Approved | CGRP ligandMonoclonal antibody | Migraine | |
| Approved | GABA transaminase (GABA-T)Small molecule | EpilepsyDevelopmental and Epileptic Encephalopathies Focal Onset Seizures | |
Vortioxetine(Trintellix) | Approved | Serotonin transporter + multiple 5-HT receptorsSmall molecule | Major Depressive Disorder |
| Phase 3 | Serotonin 5-HT2C receptor (agonist)Small molecule | Epilepsy | |
| Phase 2 | D1/D2Small molecule | Parkinson's Disease |
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
March 2027 (1)
What to watch
July 2027 (1)
What to watch
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (2)
2029 (1)
September 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q4 | — | — | — | — | report ↗ |